Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
With
Parexel
Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This study consists of a screening period of up to 28 days, followed by a treatment period of 18 weeks, and an end of study visit 3 weeks after the last dose of investigational product or study-specified chemotherapy. After randomization, subjects will receive investigational product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4 and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed non-squamous NSCLC.
Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 and no more than 6 cycles of chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
You may not be if
Small cell lung cancer (SCLC) or mixed SCLC and NSCLC.
Central nervous system (CNS) metastases.
Malignancy other than NSCLC.
Palliative radiotherapy for bone lesions inside the thorax.
Prior radiotherapy of bone marrow.
Active hepatitis B.
Active hepatitis C.
Tested positive for human immunodeficiency virus (HIV).
Life expectancy \< 6 months.
Woman of childbearing potential who is pregnant or is breast feeding.
Woman of childbearing potential who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment.
Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment.